Safety evaluation of large sample of moxifloxacin-induced liver injury and the effect of immune response and gene polymorphism in its occurrence mechanism

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800016966

Enrollment

Unknown

Registered

2018-07-05

Start date

2018-01-01

Completion date

Unknown

Last updated

2018-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

drug-induced liver injury

Interventions

case group:nil

control group:nil

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. patients older than 18 years; 2. moxifloxacin was used to treat or prevent infection during the research; 3. patients and their families have informed consent and signed informed consent.

Exclusion criteria

Exclusion criteria: 1. patients that are diagnosed with liver injury or liver failure before treatment; 2. patients that are known or suspected paracetamol overdose as well as with a history of bone marrow or liver transplant; 3. relevant clinical information is missing.

Design outcomes

Primary

Measure	Time frame
ALT;ALP;Tbil;jaundice;	—

Countries

China

Contacts

Public ContactGuo Daihong

Chinese PLA General Hospital

guodh301@163.com+86 13910153966

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026